Magnevist

Gadopentetate dimeglumine, the active ingredient in Magnevist, is a gadolinium‑based contrast agent presented as a sterile injectable solution for intravenous administration. It shortens T1 relaxation times of nearby water protons, thereby increasing signal intensity on magnetic resonance imaging. The agent is employed to improve visualization of vascular structures and tissue differentiation in MRI examinations of the brain, spine, and other body regions.

GNH USA supplies Magnevist as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, imaging centres and clinics and research institutions worldwide.

Magnevist (gadopentetate dimeglumine) is used as a contrast agent for magnetic resonance imaging to enhance visualization of anatomical structures.

- Brain MRI: improves detection and delineation of lesions, tumors, and vascular abnormalities. - Spinal MRI: enhances visualization of disc pathology, spinal cord lesions, and vascular malformations. - Abdominal and pelvic MRI: provides better contrast of organs and vascular structures for diagnostic assessment.

Magnevist may cause a range of adverse reactions following intravenous administration.

Common Side Effects: - Nausea: mild to moderate feeling of stomach upset. - Headache: transient discomfort after injection. - Injection site pain or warmth: sensation of heat or mild pain at the infusion site. - Metallic taste: brief metallic sensation in the mouth. - Vomiting: occasional episodes following the procedure.

Serious or Rare Side Effects: - Allergic reactions: including anaphylaxis, rash, or bronchospasm. - Nephrogenic systemic fibrosis (NSF): rare fibrotic disorder in patients with severe renal impairment. - Severe hypotension: sudden drop in blood pressure requiring medical intervention. - Seizures: rare neurologic events. - Cardiac arrest: extremely rare but life‑threatening event.

Use of Magnevist requires careful assessment and monitoring to minimise risk.

- Assess renal function: evaluate creatinine clearance before administration. - Use with caution in patients with impaired renal function: consider alternative agents or reduced dose. - Monitor for allergic reactions: observe patient during and after injection. - Avoid in patients with known gadolinium hypersensitivity: contraindicated. - Administer under radiologist or qualified physician supervision: ensure appropriate imaging protocol. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Magnevist may interact with other medicines that affect renal function or cause hypersensitivity.

Major Interactions (Avoid): - Renal toxic agents (e.g., high‑dose aminoglycosides): increased risk of nephrotoxicity. - Other gadolinium‑based contrast agents: cumulative gadolinium exposure. - Nephrotoxic chemotherapy (e.g., cisplatin): heightened renal risk.

Moderate Interactions (Monitor Closely): - Loop diuretics: may alter renal clearance of gadolinium. - Beta‑blockers: may mask hypotensive reactions. - Antihistamines: may reduce severity of mild allergic responses.